Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

NCT05470140 is registered in ClinicalTrials.gov with Allotera Therapeutics as lead sponsor.

NCT NCT05470140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05470140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Lead sponsor
Allotera Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2023
Completion date
October 8, 2024
Enrollment
9 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia